Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy. This study aimed to identify risk factors associated with high ADA levels in AS patients treated with CT-P13. Methods: A prospective observational study enrolled patients with intravenous CT-P13. Clinical data and disease activity was assessed at baseline, 24 weeks, and 54 weeks after CT-P13 treatment. Blood concentrations of CT-P13 and ADAs were measured at 24 and 54 weeks, and their correlation was investigated. Patients were grouped by ADA levels at 54 weeks. Univariable and multivariable logistic regression identified factors associated with high ADA concentrations. Results: A total of 34 patients was enrolled. Significant decreases in Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index scores were observed relative to baseline after 24 weeks of CT-P13 therapy. Serum concentrations of CT-P13 and ADA levels increased following treatment. The median serum CT-P13 concentration was 17.6 [12.8, 22.7] µg/mL at 24 weeks and 23.5 [11.7, 34.2] µg/mL at 54 weeks. ADA levels were 6.7 [6.5, 9.1] AU/mL at 24 weeks and 11.4 [9.0, 28.4] AU/mL at 54 weeks. The serum concentrations of CT-P13 and ADA exhibited a negative correlation. In multivariable analysis, current smoking was associated with high ADA production at 54 weeks. Conclusion Smoking is identified as a significant risk factor for elevated ADAs in AS patients treated with CT-P13. The findings underscore the importance of smoking-cessation strategies in the management of AS patients.

Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy. This study aimed to identify risk factors associated with high ADA levels in AS patients treated with CT-P13. Methods: A prospective observational study enrolled patients with intravenous CT-P13. Clinical data and disease activity was assessed at baseline, 24 weeks, and 54 weeks after CT-P13 treatment. Blood concentrations of CT-P13 and ADAs were measured at 24 and 54 weeks, and their correlation was investigated. Patients were grouped by ADA levels at 54 weeks. Univariable and multivariable logistic regression identified factors associated with high ADA concentrations. Results: A total of 34 patients was enrolled. Significant decreases in Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index scores were observed relative to baseline after 24 weeks of CT-P13 therapy. Serum concentrations of CT-P13 and ADA levels increased following treatment. The median serum CT-P13 concentration was 17.6 [12.8, 22.7] µg/mL at 24 weeks and 23.5 [11.7, 34.2] µg/mL at 54 weeks. ADA levels were 6.7 [6.5, 9.1] AU/mL at 24 weeks and 11.4 [9.0, 28.4] AU/mL at 54 weeks. The serum concentrations of CT-P13 and ADA exhibited a negative correlation. In multivariable analysis, current smoking was associated with high ADA production at 54 weeks. Conclusion Smoking is identified as a significant risk factor for elevated ADAs in AS patients treated with CT-P13. The findings underscore the importance of smoking-cessation strategies in the management of AS patients.

Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy. This study aimed to identify risk factors associated with high ADA levels in AS patients treated with CT-P13. Methods: A prospective observational study enrolled patients with intravenous CT-P13. Clinical data and disease activity was assessed at baseline, 24 weeks, and 54 weeks after CT-P13 treatment. Blood concentrations of CT-P13 and ADAs were measured at 24 and 54 weeks, and their correlation was investigated. Patients were grouped by ADA levels at 54 weeks. Univariable and multivariable logistic regression identified factors associated with high ADA concentrations. Results: A total of 34 patients was enrolled. Significant decreases in Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index scores were observed relative to baseline after 24 weeks of CT-P13 therapy. Serum concentrations of CT-P13 and ADA levels increased following treatment. The median serum CT-P13 concentration was 17.6 [12.8, 22.7] µg/mL at 24 weeks and 23.5 [11.7, 34.2] µg/mL at 54 weeks. ADA levels were 6.7 [6.5, 9.1] AU/mL at 24 weeks and 11.4 [9.0, 28.4] AU/mL at 54 weeks. The serum concentrations of CT-P13 and ADA exhibited a negative correlation. In multivariable analysis, current smoking was associated with high ADA production at 54 weeks. Conclusion Smoking is identified as a significant risk factor for elevated ADAs in AS patients treated with CT-P13. The findings underscore the importance of smoking-cessation strategies in the management of AS patients.

Snapping sensations in fingers commonly lead to diagnoses of trigger finger, usually attributed to A1 pulley pathology. However, less common etiologies can present challenges in accurate diagnosis and management. Here, we present a 70-year-old woman with right middle finger snapping, initially diagnosed as trigger finger but unresponsive to corticosteroid injection at the A1 pulley. Physical examination revealed snapping during right third proximal interphalangeal joint flexion. Ultrasound imaging revealed the lateral band’s anomalous movement during flexion, confirming the diagnosis. Conservative management was chosen due to the patient’s preference and mild symptoms. This case highlights the importance of considering uncommon causes of finger snapping and underscores the value of ultrasound in diagnosis, contributing to enhanced clinical recognition and utility of ultrasound for such rare pathologies.

Snapping sensations in fingers commonly lead to diagnoses of trigger finger, usually attributed to A1 pulley pathology. However, less common etiologies can present challenges in accurate diagnosis and management. Here, we present a 70-year-old woman with right middle finger snapping, initially diagnosed as trigger finger but unresponsive to corticosteroid injection at the A1 pulley. Physical examination revealed snapping during right third proximal interphalangeal joint flexion. Ultrasound imaging revealed the lateral band’s anomalous movement during flexion, confirming the diagnosis. Conservative management was chosen due to the patient’s preference and mild symptoms. This case highlights the importance of considering uncommon causes of finger snapping and underscores the value of ultrasound in diagnosis, contributing to enhanced clinical recognition and utility of ultrasound for such rare pathologies.

Snapping sensations in fingers commonly lead to diagnoses of trigger finger, usually attributed to A1 pulley pathology. However, less common etiologies can present challenges in accurate diagnosis and management. Here, we present a 70-year-old woman with right middle finger snapping, initially diagnosed as trigger finger but unresponsive to corticosteroid injection at the A1 pulley. Physical examination revealed snapping during right third proximal interphalangeal joint flexion. Ultrasound imaging revealed the lateral band’s anomalous movement during flexion, confirming the diagnosis. Conservative management was chosen due to the patient’s preference and mild symptoms. This case highlights the importance of considering uncommon causes of finger snapping and underscores the value of ultrasound in diagnosis, contributing to enhanced clinical recognition and utility of ultrasound for such rare pathologies.

Snapping sensations in fingers commonly lead to diagnoses of trigger finger, usually attributed to A1 pulley pathology. However, less common etiologies can present challenges in accurate diagnosis and management. Here, we present a 70-year-old woman with right middle finger snapping, initially diagnosed as trigger finger but unresponsive to corticosteroid injection at the A1 pulley. Physical examination revealed snapping during right third proximal interphalangeal joint flexion. Ultrasound imaging revealed the lateral band’s anomalous movement during flexion, confirming the diagnosis. Conservative management was chosen due to the patient’s preference and mild symptoms. This case highlights the importance of considering uncommon causes of finger snapping and underscores the value of ultrasound in diagnosis, contributing to enhanced clinical recognition and utility of ultrasound for such rare pathologies.

PURPOSE: The purpose of this study was to investigate the extent and the nature of biological nursing science education for clinical nurses in general hospital. METHODS: Five advanced general hospitals located in Seoul and Gyeonggi province were conveniently sampled. Contents of education for nurses conducted by the hospital nursing department from January 1 to December 31 of 2015 were collected. Contents of education included biological nursing science and the scope of inclusion and time of assignment were analyzed. RESULTS: A total of 271 cases of nursing education data were collected and 223 cases were analyzed after excluding 48 cases whose contents were not confirmed. Biological nursing science was included in the contents of education for 117 cases (52.5%), but not for 106 cases (47.5%). Regarding the frequency of the biological nursing science education contents, ‘pathophysiology’was the most frequently included (n=286), followed by ‘structure and function of the human body’ (n=191), ‘mechanisms and effects of drugs’ (n=114) and ‘clinical microbiology’ (n=43). CONCLUSION: Results of this study confirmed that the education for clinical nurses included a lot of biological nursing science related contents. These results can be used as basis for the development of curriculum and training course for nurses.
Curriculum ; Education ; Education, Nursing ; Gyeonggi-do ; Hospitals, General ; Humans ; Nursing ; Seoul

OBJECTIVE: To investigate changes of cardiac and muscle damage markers in exercise-induced hypertension (EIH) runners before running (pre-race), immediately after completing a 100-km ultramarathon race, and during the recovery period (24, 72, and 120 hours post-race). METHODS: In this observational study, volunteers were divided into EIH group (n=11) whose maximum systolic blood pressure was ≥210 mmHg in graded exercise testing and normal exercise blood pressure response (NEBPR) group (n=11). Their blood samples were collected at pre-race, immediately after race, and at 24, 72, and 120 hours post-race. RESULTS: Creatine kinase (CK) and cardiac troponin I (cTnI) levels were significantly higher in EIH group than those in the NEBPR group immediately after race and at 24 hours post-race (all p < 0.05). However, lactate dehydrogenase (LDH), creatine kinase-myocardial band (CKMB), or CKMB/CK levels did not show any significant differences between the two groups in each period. N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were significantly higher in EIH group than those in NEBPR group immediately after race and at 24 and 72 hours post-race (all p < 0.05). A high sensitivity C-reactive protein (hs-CRP) level was significantly higher in EIH group than that in NEBPR group at 24 hours post-race (p < 0.05). CONCLUSION: The phenomenon of higher inflammatory and cardiac marker levels in EIH group may exaggerate cardiac volume pressure and blood flow restrictions which in turn can result in cardiac muscle damage. Further prospective studies are needed to investigate the chronic effect of such phenomenon on the cardiovascular system in EIH runners.
Biomarkers* ; Blood Pressure ; C-Reactive Protein ; Cardiac Volume ; Cardiovascular System ; Continental Population Groups ; Creatine ; Creatine Kinase ; Exercise Test ; Humans ; Hypertension* ; L-Lactate Dehydrogenase ; Myocardium ; Observational Study* ; Prospective Studies ; Running* ; Troponin I ; Volunteers

PURPOSE: Changes in serum biomarkers of cardiac and muscle damage have been studied in ultra-marathon runners for distances up to 308 km. We investigated these biomarker changes following a 622-km super-ultramarathon race. METHODS: A group of men with a mean age of 52.7±4.8 years participated. Blood samples were obtained pre-race, during the race, and post-race, to analyze the aforementioned biomarkers. RESULTS: Creatine kinase and creatine kinase-MB (CK-MB) levels increased during the race, and both steadily declined post-race with CK-MB declining at a slower rate. Lactic acid dehydrogenase levels overall were increased over pre-race levels. White blood cell counts increased during the race. Red blood cell decreased from pre-race to 300 km and 622 km. Platelet increased only in the recovery period. High-sensitivity C-reactive protein levels were increased throughout the race and at day 3 compared to pre-race levels. Cardiac troponin I (cTnI) levels increased during the race. N-terminal pro b-type natriuretic peptide (NT-proBNP) levels increased during the race. CONCLUSION: The rise in cTnI was not clinically significant, and highly elevated NT-proBNP levels during the race indicates that myocardial burden rose linearly as running distance increased. However, no clinical risk was found as most of the markers returned to normal range during the recovery.
Biomarkers ; Blood Platelets ; C-Reactive Protein ; Continental Population Groups* ; Creatine ; Creatine Kinase ; Erythrocytes ; Humans ; Lactic Acid ; Leukocyte Count ; Male ; Natriuretic Peptide, Brain ; Oxidoreductases ; Reference Values ; Rhabdomyolysis ; Running ; Troponin I